Stockreport

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data [Seeking Alpha]

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF Summary Repare Therapeutics Inc. results from phase 1 MYTHIC study, using lunresertib + camonsertib for the treatment of platinum-resistant ovarian and endometrial ca [Read more]